Two oral contraceptives, efficacy, serum proteins, and lipid metabolism: A comparative multicentre study on a triphasic and a fixed dose combination

A triphasic, combined oral contraceptive containing 30 — 40 — 30 μg ethinyloestradiol (EE), and 50 — 75 — 125 μg levonorgestrel was compared with a fixed dose combination containing 30 μg EE and 150 μg desogestrel in a randomized multicentre trial in 193/199 women and 1063/1073 cycles, respectively....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Contraception (Stoneham) 1982-09, Vol.26 (3), p.229-243
Hauptverfasser: Cullberg, Göran, Samsioe, Göran, Andersen, Randi Finstad, Bredesgaard, Preben, Andersen, Nicolai Boe, Ernerot, Hans, Fanøe, Erik, Fylling, Petter, Haack-Sørensen, Paul-Erik, Klottrup, Paul, Pedersen, Jørgen H, Sandager, Torben
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 243
container_issue 3
container_start_page 229
container_title Contraception (Stoneham)
container_volume 26
creator Cullberg, Göran
Samsioe, Göran
Andersen, Randi Finstad
Bredesgaard, Preben
Andersen, Nicolai Boe
Ernerot, Hans
Fanøe, Erik
Fylling, Petter
Haack-Sørensen, Paul-Erik
Klottrup, Paul
Pedersen, Jørgen H
Sandager, Torben
description A triphasic, combined oral contraceptive containing 30 — 40 — 30 μg ethinyloestradiol (EE), and 50 — 75 — 125 μg levonorgestrel was compared with a fixed dose combination containing 30 μg EE and 150 μg desogestrel in a randomized multicentre trial in 193/199 women and 1063/1073 cycles, respectively. The duration of the trial was six months. Eleven centres in Denmark, Sweden, and Norway participated. Contraceptive reliability, bleeding control and side effects were evaluated. Influence on serum sex hormone binding globulin (SHBG) and transcortin was assayed as well as lipid metabolism. Three pregnancies occurred in the group using the triphasic regimen but none in the fixed dose regimen. Two of the three pregnancies were considered drug failures and the third a possible interaction. Possible reasons for the triphasic contraceptive failure are discussed with special reference to a British report on eight pregnancies. Bleeding control appeared to be equally good for the two preparations. However, the number of cycles with spotting, breakthrough bleeding and missed withdrawal bleeding were above the levels reported earlier on the triphasic regimen. About 80 per cent of the women completed the planned six months on either combination. Side effects were generally mild and in accordance with earlier reports on low dose oral contraceptives. Metabolically the triphasic levonorgestrel combination increased SHBG 100 per cent versus 200 per cent for the fixed desogestrel combination. Transcortin rose about 98 and 110 per cent, respectively. Both preparations induced similar changes in the levels of lipids and lipoproteins with the exception of a significant increase in the arachidonic content of cholesterol during treatment with the desogestrel-containing preparation.
doi_str_mv 10.1016/0010-7824(82)90072-5
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_80216370</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0010782482900725</els_id><sourcerecordid>80216370</sourcerecordid><originalsourceid>FETCH-LOGICAL-e201t-fea8b991008c7bcc795d8c356a96c794fb2727c891b51d133e98a2b4e90813483</originalsourceid><addsrcrecordid>eNo9UV1LHTEQDaVib23_gYU8lRZcTbJ3N4kPBZG2CoIv9jlkk1mcsrvZJlnt_R_-YLN68WkYzgdz5hByzNkpZ7w9Y4yzSiqx_abEd82YFFXzjmy4krpiDVfvyeaN8oF8TOkvKyTdyENy2AoumVAb8nT3GGiIdqAuTDlaB3PGB0gnFPoenXW7E5ogLiOdY8iAU0Hs5OmAM3o6QrZdGDCN5_SiOIyzjXbV03EZMjoolkBTXvyOholamiPO9zahezGxtMf_4KkPCVZ1h1NRh-kTOejtkODzfh6RP79-3l1eVTe3v68vL24qEIznqgerOq05Y8rJzrmSzStXN63VbVm2fSekkE5p3jXc87oGrazotqCZ4vVW1Ufk66tvyfZvgZTNiMnBMNgJwpKMYoK3tWSF-GVPXLoRvJkjjjbuzP6NBf_xikO59gEhmuQQJgceI7hsfEDDmVlrM2snZu3EKGFeajNN_QzTBIry</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80216370</pqid></control><display><type>article</type><title>Two oral contraceptives, efficacy, serum proteins, and lipid metabolism: A comparative multicentre study on a triphasic and a fixed dose combination</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Cullberg, Göran ; Samsioe, Göran ; Andersen, Randi Finstad ; Bredesgaard, Preben ; Andersen, Nicolai Boe ; Ernerot, Hans ; Fanøe, Erik ; Fylling, Petter ; Haack-Sørensen, Paul-Erik ; Klottrup, Paul ; Pedersen, Jørgen H ; Sandager, Torben</creator><creatorcontrib>Cullberg, Göran ; Samsioe, Göran ; Andersen, Randi Finstad ; Bredesgaard, Preben ; Andersen, Nicolai Boe ; Ernerot, Hans ; Fanøe, Erik ; Fylling, Petter ; Haack-Sørensen, Paul-Erik ; Klottrup, Paul ; Pedersen, Jørgen H ; Sandager, Torben</creatorcontrib><description>A triphasic, combined oral contraceptive containing 30 — 40 — 30 μg ethinyloestradiol (EE), and 50 — 75 — 125 μg levonorgestrel was compared with a fixed dose combination containing 30 μg EE and 150 μg desogestrel in a randomized multicentre trial in 193/199 women and 1063/1073 cycles, respectively. The duration of the trial was six months. Eleven centres in Denmark, Sweden, and Norway participated. Contraceptive reliability, bleeding control and side effects were evaluated. Influence on serum sex hormone binding globulin (SHBG) and transcortin was assayed as well as lipid metabolism. Three pregnancies occurred in the group using the triphasic regimen but none in the fixed dose regimen. Two of the three pregnancies were considered drug failures and the third a possible interaction. Possible reasons for the triphasic contraceptive failure are discussed with special reference to a British report on eight pregnancies. Bleeding control appeared to be equally good for the two preparations. However, the number of cycles with spotting, breakthrough bleeding and missed withdrawal bleeding were above the levels reported earlier on the triphasic regimen. About 80 per cent of the women completed the planned six months on either combination. Side effects were generally mild and in accordance with earlier reports on low dose oral contraceptives. Metabolically the triphasic levonorgestrel combination increased SHBG 100 per cent versus 200 per cent for the fixed desogestrel combination. Transcortin rose about 98 and 110 per cent, respectively. Both preparations induced similar changes in the levels of lipids and lipoproteins with the exception of a significant increase in the arachidonic content of cholesterol during treatment with the desogestrel-containing preparation.</description><identifier>ISSN: 0010-7824</identifier><identifier>EISSN: 1879-0518</identifier><identifier>DOI: 10.1016/0010-7824(82)90072-5</identifier><identifier>PMID: 6217028</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Blood Proteins - metabolism ; Clinical Trials as Topic ; Contraceptives, Oral - administration &amp; dosage ; Contraceptives, Oral, Combined - administration &amp; dosage ; Denmark ; Desogestrel ; Dose-Response Relationship, Drug ; Ethinyl Estradiol - administration &amp; dosage ; Fatty Acids - blood ; Female ; Humans ; Levonorgestrel ; Lipids - blood ; Lipoproteins - blood ; Norgestrel - administration &amp; dosage ; Norpregnenes - administration &amp; dosage ; Norway ; Population ; Pregnancy ; Sex Hormone-Binding Globulin - metabolism ; Sweden ; Transcortin - metabolism</subject><ispartof>Contraception (Stoneham), 1982-09, Vol.26 (3), p.229-243</ispartof><rights>1982</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0010-7824(82)90072-5$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6217028$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cullberg, Göran</creatorcontrib><creatorcontrib>Samsioe, Göran</creatorcontrib><creatorcontrib>Andersen, Randi Finstad</creatorcontrib><creatorcontrib>Bredesgaard, Preben</creatorcontrib><creatorcontrib>Andersen, Nicolai Boe</creatorcontrib><creatorcontrib>Ernerot, Hans</creatorcontrib><creatorcontrib>Fanøe, Erik</creatorcontrib><creatorcontrib>Fylling, Petter</creatorcontrib><creatorcontrib>Haack-Sørensen, Paul-Erik</creatorcontrib><creatorcontrib>Klottrup, Paul</creatorcontrib><creatorcontrib>Pedersen, Jørgen H</creatorcontrib><creatorcontrib>Sandager, Torben</creatorcontrib><title>Two oral contraceptives, efficacy, serum proteins, and lipid metabolism: A comparative multicentre study on a triphasic and a fixed dose combination</title><title>Contraception (Stoneham)</title><addtitle>Contraception</addtitle><description>A triphasic, combined oral contraceptive containing 30 — 40 — 30 μg ethinyloestradiol (EE), and 50 — 75 — 125 μg levonorgestrel was compared with a fixed dose combination containing 30 μg EE and 150 μg desogestrel in a randomized multicentre trial in 193/199 women and 1063/1073 cycles, respectively. The duration of the trial was six months. Eleven centres in Denmark, Sweden, and Norway participated. Contraceptive reliability, bleeding control and side effects were evaluated. Influence on serum sex hormone binding globulin (SHBG) and transcortin was assayed as well as lipid metabolism. Three pregnancies occurred in the group using the triphasic regimen but none in the fixed dose regimen. Two of the three pregnancies were considered drug failures and the third a possible interaction. Possible reasons for the triphasic contraceptive failure are discussed with special reference to a British report on eight pregnancies. Bleeding control appeared to be equally good for the two preparations. However, the number of cycles with spotting, breakthrough bleeding and missed withdrawal bleeding were above the levels reported earlier on the triphasic regimen. About 80 per cent of the women completed the planned six months on either combination. Side effects were generally mild and in accordance with earlier reports on low dose oral contraceptives. Metabolically the triphasic levonorgestrel combination increased SHBG 100 per cent versus 200 per cent for the fixed desogestrel combination. Transcortin rose about 98 and 110 per cent, respectively. Both preparations induced similar changes in the levels of lipids and lipoproteins with the exception of a significant increase in the arachidonic content of cholesterol during treatment with the desogestrel-containing preparation.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Blood Proteins - metabolism</subject><subject>Clinical Trials as Topic</subject><subject>Contraceptives, Oral - administration &amp; dosage</subject><subject>Contraceptives, Oral, Combined - administration &amp; dosage</subject><subject>Denmark</subject><subject>Desogestrel</subject><subject>Dose-Response Relationship, Drug</subject><subject>Ethinyl Estradiol - administration &amp; dosage</subject><subject>Fatty Acids - blood</subject><subject>Female</subject><subject>Humans</subject><subject>Levonorgestrel</subject><subject>Lipids - blood</subject><subject>Lipoproteins - blood</subject><subject>Norgestrel - administration &amp; dosage</subject><subject>Norpregnenes - administration &amp; dosage</subject><subject>Norway</subject><subject>Population</subject><subject>Pregnancy</subject><subject>Sex Hormone-Binding Globulin - metabolism</subject><subject>Sweden</subject><subject>Transcortin - metabolism</subject><issn>0010-7824</issn><issn>1879-0518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1982</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UV1LHTEQDaVib23_gYU8lRZcTbJ3N4kPBZG2CoIv9jlkk1mcsrvZJlnt_R_-YLN68WkYzgdz5hByzNkpZ7w9Y4yzSiqx_abEd82YFFXzjmy4krpiDVfvyeaN8oF8TOkvKyTdyENy2AoumVAb8nT3GGiIdqAuTDlaB3PGB0gnFPoenXW7E5ogLiOdY8iAU0Hs5OmAM3o6QrZdGDCN5_SiOIyzjXbV03EZMjoolkBTXvyOholamiPO9zahezGxtMf_4KkPCVZ1h1NRh-kTOejtkODzfh6RP79-3l1eVTe3v68vL24qEIznqgerOq05Y8rJzrmSzStXN63VbVm2fSekkE5p3jXc87oGrazotqCZ4vVW1Ufk66tvyfZvgZTNiMnBMNgJwpKMYoK3tWSF-GVPXLoRvJkjjjbuzP6NBf_xikO59gEhmuQQJgceI7hsfEDDmVlrM2snZu3EKGFeajNN_QzTBIry</recordid><startdate>198209</startdate><enddate>198209</enddate><creator>Cullberg, Göran</creator><creator>Samsioe, Göran</creator><creator>Andersen, Randi Finstad</creator><creator>Bredesgaard, Preben</creator><creator>Andersen, Nicolai Boe</creator><creator>Ernerot, Hans</creator><creator>Fanøe, Erik</creator><creator>Fylling, Petter</creator><creator>Haack-Sørensen, Paul-Erik</creator><creator>Klottrup, Paul</creator><creator>Pedersen, Jørgen H</creator><creator>Sandager, Torben</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>198209</creationdate><title>Two oral contraceptives, efficacy, serum proteins, and lipid metabolism: A comparative multicentre study on a triphasic and a fixed dose combination</title><author>Cullberg, Göran ; Samsioe, Göran ; Andersen, Randi Finstad ; Bredesgaard, Preben ; Andersen, Nicolai Boe ; Ernerot, Hans ; Fanøe, Erik ; Fylling, Petter ; Haack-Sørensen, Paul-Erik ; Klottrup, Paul ; Pedersen, Jørgen H ; Sandager, Torben</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e201t-fea8b991008c7bcc795d8c356a96c794fb2727c891b51d133e98a2b4e90813483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1982</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Blood Proteins - metabolism</topic><topic>Clinical Trials as Topic</topic><topic>Contraceptives, Oral - administration &amp; dosage</topic><topic>Contraceptives, Oral, Combined - administration &amp; dosage</topic><topic>Denmark</topic><topic>Desogestrel</topic><topic>Dose-Response Relationship, Drug</topic><topic>Ethinyl Estradiol - administration &amp; dosage</topic><topic>Fatty Acids - blood</topic><topic>Female</topic><topic>Humans</topic><topic>Levonorgestrel</topic><topic>Lipids - blood</topic><topic>Lipoproteins - blood</topic><topic>Norgestrel - administration &amp; dosage</topic><topic>Norpregnenes - administration &amp; dosage</topic><topic>Norway</topic><topic>Population</topic><topic>Pregnancy</topic><topic>Sex Hormone-Binding Globulin - metabolism</topic><topic>Sweden</topic><topic>Transcortin - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cullberg, Göran</creatorcontrib><creatorcontrib>Samsioe, Göran</creatorcontrib><creatorcontrib>Andersen, Randi Finstad</creatorcontrib><creatorcontrib>Bredesgaard, Preben</creatorcontrib><creatorcontrib>Andersen, Nicolai Boe</creatorcontrib><creatorcontrib>Ernerot, Hans</creatorcontrib><creatorcontrib>Fanøe, Erik</creatorcontrib><creatorcontrib>Fylling, Petter</creatorcontrib><creatorcontrib>Haack-Sørensen, Paul-Erik</creatorcontrib><creatorcontrib>Klottrup, Paul</creatorcontrib><creatorcontrib>Pedersen, Jørgen H</creatorcontrib><creatorcontrib>Sandager, Torben</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Contraception (Stoneham)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cullberg, Göran</au><au>Samsioe, Göran</au><au>Andersen, Randi Finstad</au><au>Bredesgaard, Preben</au><au>Andersen, Nicolai Boe</au><au>Ernerot, Hans</au><au>Fanøe, Erik</au><au>Fylling, Petter</au><au>Haack-Sørensen, Paul-Erik</au><au>Klottrup, Paul</au><au>Pedersen, Jørgen H</au><au>Sandager, Torben</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Two oral contraceptives, efficacy, serum proteins, and lipid metabolism: A comparative multicentre study on a triphasic and a fixed dose combination</atitle><jtitle>Contraception (Stoneham)</jtitle><addtitle>Contraception</addtitle><date>1982-09</date><risdate>1982</risdate><volume>26</volume><issue>3</issue><spage>229</spage><epage>243</epage><pages>229-243</pages><issn>0010-7824</issn><eissn>1879-0518</eissn><abstract>A triphasic, combined oral contraceptive containing 30 — 40 — 30 μg ethinyloestradiol (EE), and 50 — 75 — 125 μg levonorgestrel was compared with a fixed dose combination containing 30 μg EE and 150 μg desogestrel in a randomized multicentre trial in 193/199 women and 1063/1073 cycles, respectively. The duration of the trial was six months. Eleven centres in Denmark, Sweden, and Norway participated. Contraceptive reliability, bleeding control and side effects were evaluated. Influence on serum sex hormone binding globulin (SHBG) and transcortin was assayed as well as lipid metabolism. Three pregnancies occurred in the group using the triphasic regimen but none in the fixed dose regimen. Two of the three pregnancies were considered drug failures and the third a possible interaction. Possible reasons for the triphasic contraceptive failure are discussed with special reference to a British report on eight pregnancies. Bleeding control appeared to be equally good for the two preparations. However, the number of cycles with spotting, breakthrough bleeding and missed withdrawal bleeding were above the levels reported earlier on the triphasic regimen. About 80 per cent of the women completed the planned six months on either combination. Side effects were generally mild and in accordance with earlier reports on low dose oral contraceptives. Metabolically the triphasic levonorgestrel combination increased SHBG 100 per cent versus 200 per cent for the fixed desogestrel combination. Transcortin rose about 98 and 110 per cent, respectively. Both preparations induced similar changes in the levels of lipids and lipoproteins with the exception of a significant increase in the arachidonic content of cholesterol during treatment with the desogestrel-containing preparation.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>6217028</pmid><doi>10.1016/0010-7824(82)90072-5</doi><tpages>15</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0010-7824
ispartof Contraception (Stoneham), 1982-09, Vol.26 (3), p.229-243
issn 0010-7824
1879-0518
language eng
recordid cdi_proquest_miscellaneous_80216370
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Adolescent
Adult
Blood Proteins - metabolism
Clinical Trials as Topic
Contraceptives, Oral - administration & dosage
Contraceptives, Oral, Combined - administration & dosage
Denmark
Desogestrel
Dose-Response Relationship, Drug
Ethinyl Estradiol - administration & dosage
Fatty Acids - blood
Female
Humans
Levonorgestrel
Lipids - blood
Lipoproteins - blood
Norgestrel - administration & dosage
Norpregnenes - administration & dosage
Norway
Population
Pregnancy
Sex Hormone-Binding Globulin - metabolism
Sweden
Transcortin - metabolism
title Two oral contraceptives, efficacy, serum proteins, and lipid metabolism: A comparative multicentre study on a triphasic and a fixed dose combination
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T00%3A48%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Two%20oral%20contraceptives,%20efficacy,%20serum%20proteins,%20and%20lipid%20metabolism:%20A%20comparative%20multicentre%20study%20on%20a%20triphasic%20and%20a%20fixed%20dose%20combination&rft.jtitle=Contraception%20(Stoneham)&rft.au=Cullberg,%20G%C3%B6ran&rft.date=1982-09&rft.volume=26&rft.issue=3&rft.spage=229&rft.epage=243&rft.pages=229-243&rft.issn=0010-7824&rft.eissn=1879-0518&rft_id=info:doi/10.1016/0010-7824(82)90072-5&rft_dat=%3Cproquest_pubme%3E80216370%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80216370&rft_id=info:pmid/6217028&rft_els_id=0010782482900725&rfr_iscdi=true